Skip to search formSkip to main contentSkip to account menu

SAR650984

Known as: Anti-CD38 Monoclonal Antibody SAR650984, SAR6 50984 
A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Anti-CD38… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Antibodies, Monoclonal, Humanized
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Rational Design and Identification of Small‐Molecule Allosteric Inhibitors of CD38
CD38 is a multi‐functional signaling enzyme that catalyzes the biosynthesis of two calcium‐mobilizing second messengers: cyclic… 
2017
2017
Incorporating monoclonal antibodies into the management of multiple myeloma.
2016
2016
Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).
8005Background: Isatuximab (ISA) is a humanized anti-CD38 monoclonal antibody with multiple modes of action for killing tumor… 
2016
2016
A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new…
8009Background: Isatuximab (ISA), a humanized anti-CD38 monoclonal antibody, has demonstrated activity in patients (pts) with… 
2014
2014
A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Background: SAR650984 (SAR) is a humanized IgG1 monoclonal antibody that binds selectively to a unique epitope on the human CD38… 
2014
2014
A phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.
8512 Background: SAR650984 (SAR) is a humanized IgG1 monoclonal antibody that binds selectively to a unique epitope on human CD38… 
2014
2014
KIR and HLA Genotypes Influence Clinical Outcome in Multiple Myeloma Patients Treated with SAR650984 (Anti-CD38) in Combination with Lenalidomide and Dexamethasone
SAR650984 (SAR) is a humanized IgG1 monoclonal antibody that binds selectively to the human CD38 receptor. TCD11863 (TCD) is a… 
2013
2013
Abstract 4735: SAR650984: Characterization of a potent phase I humanized anti-CD38 antibody for the treatment of multiple myeloma and other hematologic malignancies.
SAR650984, a humanized antibody targeting the type II transmembrane glycoprotein CD38 is currently in phase I dose escalation in… 
2013
2013
Abstract 5469: SAR650984, an anti-CD38 antibody, shows anti-tumor activity in a preclinical model of multiple myeloma.
Multiple myeloma (MM) is the second most common cancer of the blood and one that is difficult to treat. Although survival has… 
2008
2008
SAR650984: A Potent Anti-CD38 Therapeutic Antibody with Three Mechanisms of Action (Apoptosis, ADCC, CDC) for Hematological Malignancies
CD38 is a promising target for antibody therapeutics for the treatment of various hematological malignancies, including multiple… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)